InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（1 笔）
内部人交易记录
首席执行官已披露买入
1
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the complete record of transactions filed by Renaud Ronald C JR, 首席执行官. Officer active across 4 companies, notably Atara Biotherapeutics, Inc.. Aggregated, 7 filings have been recorded. Split: 1 buy · 1 sell. Total volume traded: €1.8m. Activity tracked since 8 June 2021. The latest transaction was disclosed on 3 August 2023 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Companies and markets linked to Renaud Ronald C JR
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报7 总计
160,452 股Common StockSEC:0000950170-24-090851:0
160,452 股Common StockSEC:0000950170-23-072374:0
83,857 股@ US$23.9552100.0% 占其流量Common StockSEC:0000950170-23-039169:0
标准退出：2023年11月1日 (T+90)
20,500 股0Common StockSEC:0001140361-22-024159:0
9,026 股@ US$7.39100.0% 占其流量Common StockSEC:0001209191-21-056060:0
503,231 股@ €32.189849.8% 占其流量Common StockSEC:0001209191-21-056062:0
11,000 股0Common StockSEC:0001140361-21-020441:0
7 条申报中的 7 条
About Renaud Ronald C JR
Ronald C. Renaud Jr. is the Chief Executive Officer of Atara Biotherapeutics, Inc. and Translate Bio, Inc. In these roles, he oversees the operations and growth strategy of the biopharmaceutical companies. Renaud brings extensive experience in the biotechnology sector, contributing to innovation and treatment research. His leadership is essential for achieving product development and commercialization objectives.
